Literature DB >> 8909524

Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation.

L M Ellis1, W Liu, M Wilson.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent paracrine angiogenic factor implicated in human colon cancer angiogenesis. This study determined whether regulation of VEGF expression by human colon cancer cell lines affects endothelial cell proliferation in an in vitro model of angiogenesis.
METHODS: Human colon carcinoma cell lines were screened for VEGF mRNA expression. SW480 cells (low VEGF expresser) were transfected with the VEGF sense (VS) vector, and SW620 cells (high VEGF expresser) were transfected with the VEGF antisense (VAS) vector. Cells were transfected with the vector alone as control. Endothelial cells were grown in conditioned, serum-free medium produced from experimental cells, and proliferation was determined.
RESULTS: SW480-VS transfectants exhibited a sixfold increase in VEGF secretion. SW620-VAS transfectants exhibited a 50% reduction in VEGF secretion. Endothelial cells grown in conditioned medium from SW480-VS cells exhibited a 1.5- to 2-fold increase in proliferation. Addition of conditioned medium from SW620-VAS cells resulted in a 25% to 50% decrease in endothelial cell proliferation.
CONCLUSIONS: VEGF production by human colon cancer cells regulates endothelial cell proliferation. Antisense VEGF transfection can down-regulate VEGF secretion and biologic activity. Therapies to decrease VEGF expression may be a means of inhibiting angiogenesis in primary and metastatic colon cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909524     DOI: 10.1016/s0039-6060(96)80097-3

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Authors:  M Cecilia Subauste; Tatyana A Kupriyanova; Erin M Conn; Veronica C Ardi; James P Quigley; Elena I Deryugina
Journal:  Clin Exp Metastasis       Date:  2009-10-20       Impact factor: 5.150

2.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 3.  Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.

Authors:  Helena Verdaguer; Josep Tabernero; Teresa Macarulla
Journal:  Ther Adv Med Oncol       Date:  2016-03-11       Impact factor: 8.168

4.  EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.

Authors:  Y D Jung; M S Kim; B A Shin; K O Chay; B W Ahn; W Liu; C D Bucana; G E Gallick; L M Ellis
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

5.  Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta.

Authors:  Y Akagi; W Liu; K Xie; B Zebrowski; R M Shaheen; L M Ellis
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

6.  Angiopoietin-1 inhibits tumour growth and ascites formation in a murine model of peritoneal carcinomatosis.

Authors:  O Stoeltzing; S A Ahmad; W Liu; M F McCarty; A A Parikh; F Fan; N Reinmuth; C D Bucana; L M Ellis
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

7.  Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer.

Authors:  W Liu; Y D Jung; S A Ahmad; M F McCarty; O Stoeltzing; N Reinmuth; F Fan; L M Ellis
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

8.  Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor.

Authors:  W Shi; D W Siemann
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.